Study to Evaluate the Effects of Neramexane on the Pharmacokinetics of a Combined Drospirenone/Ethinyl Estradiol Oral Contraceptive in Healthy Female Subjects

• Status: Completed
• Trial end date: 2009-11-01

Summary

Primary:

To assess the effects of repeated dose of Neramexane on the steady-state pharmacokinetics of Drospirenone [DRSP] and Ethinyl Estradiol [EE]

Secondary:

To assess safety and tolerability of concomitant repeated dose treatments of Neramexane and a fixed-combinational DRSP- and EE-containing oral contraceptive [OC] (Yasmin®)

• Phase: Phase 1

Details

• Lead Sponsor: Merz Pharmaceuticals GmbH
• Treatments: Drospirenone and ethinyl estradiol combination; Ethinyl Estradiol